{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:26:42Z","timestamp":1792567602166,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000893","name":"Simons Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000893","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01230-y","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:03:18Z","timestamp":1740038598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["High WEE1 expression is independently linked to poor survival in multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-3565","authenticated-orcid":false,"given":"Anish K.","family":"Simhal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-9320","authenticated-orcid":false,"given":"Ross S.","family":"Firestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswatej","family":"Avutu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-6495","authenticated-orcid":false,"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":false,"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-4854","authenticated-orcid":false,"given":"Kylee H.","family":"Maclachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph O.","family":"Deasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"1230_CR1","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020\u20138.","journal-title":"Blood"},{"key":"1230_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","volume":"8","author":"P Ravi","year":"2018","unstructured":"Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8:26.","journal-title":"Blood Cancer J"},{"key":"1230_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/leu.2009.274","volume":"24","author":"NC Guti\u00e9rrez","year":"2010","unstructured":"Guti\u00e9rrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia. 2010;24:629\u201337.","journal-title":"Leukemia"},{"key":"1230_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30694-w","volume":"13","author":"M Bustoros","year":"2022","unstructured":"Bustoros M, Anand S, Sklavenitis-Pistofidis R, Redd R, Boyle EM, Zhitomirsky B, et al. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nat Commun. 2022;13:3449.","journal-title":"Nat Commun"},{"key":"1230_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41408-023-00935-2","volume":"13","author":"AK Simhal","year":"2023","unstructured":"Simhal AK, Maclachlan KH, Elkin R, Zhu J, Norton L, Deasy JO, et al. Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival. Blood Cancer J. 2023;13:175.","journal-title":"Blood Cancer J"},{"key":"1230_CR6","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, Miguel JS, Durie BGM, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"key":"1230_CR7","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"1230_CR8","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"1230_CR9","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol. 2024;42:1229\u201340.","journal-title":"J Clin Oncol"},{"key":"1230_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01076-w","volume":"14","author":"GR Mohyuddin","year":"2024","unstructured":"Mohyuddin GR, Rubinstein SM, Kumar S, Rajkumar SV, Fonseca R, Abdallah NH, et al. Performance of newer myeloma staging systems in a contemporary, large patient cohort. Blood Cancer J. 2024;14:95.","journal-title":"Blood Cancer J"},{"key":"1230_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.clml.2017.06.020","volume":"17","author":"EH van Beers","year":"2017","unstructured":"van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, et al. Prognostic validation of SKY92 and its combination with ISS in an independent cohort of patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2017;17:555\u201362.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1230_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/leu.2015.309","volume":"30","author":"N Weinhold","year":"2016","unstructured":"Weinhold N, Heuck CJ, Rosenthal A, Thanendrarajan S, Stein CK, Van Rhee F, et al. Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia. 2016;30:423\u201330.","journal-title":"Leukemia"},{"key":"1230_CR13","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy Jr","year":"2007","unstructured":"Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276\u201384.","journal-title":"Blood"},{"key":"1230_CR14","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1242\/jcs.00908","volume":"116","author":"DR Kellogg","year":"2003","unstructured":"Kellogg DR. WEE1-dependent mechanisms required for coordination of cell growth and cell division. J Cell Sci. 2003;116:4883\u201390.","journal-title":"J Cell Sci"},{"key":"1230_CR15","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.tig.2013.02.003","volume":"29","author":"K Mahajan","year":"2013","unstructured":"Mahajan K, Mahajan NP. WEE1 tyrosine kinase, a novel epigenetic modifier. Trends Genet. 2013;29:394\u2013402.","journal-title":"Trends Genet"},{"key":"1230_CR16","doi-asserted-by":"publisher","first-page":"49902","DOI":"10.18632\/oncotarget.10231","volume":"7","author":"H-Y Kim","year":"2016","unstructured":"Kim H-Y, Cho Y, Kang H, Yim Y-S, Kim S-J, Song J, et al. Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. Oncotarget. 2016;7:49902\u201316.","journal-title":"Oncotarget"},{"key":"1230_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.cell.2005.05.029","volume":"122","author":"SL Harvey","year":"2005","unstructured":"Harvey SL, Charlet A, Haas W, Gygi SP, Kellogg DR. Cdk1-dependent regulation of the mitotic inhibitor WEE1. Cell. 2005;122:407\u201320.","journal-title":"Cell"},{"key":"1230_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7150\/ijbs.2.161","volume":"2","author":"Y Tominaga","year":"2006","unstructured":"Tominaga Y, Li C, Wang R-H, Deng C-X. Murine WEE1 plays a critical role in cell cycle regulation and pre-implantation stages of embryonic development. Int J Biol Sci. 2006;2:161\u201370.","journal-title":"Int J Biol Sci"},{"key":"1230_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110310","volume":"94","author":"S-B Koh","year":"2022","unstructured":"Koh S-B. The expanding role of WEE1. Cell Signal. 2022;94:110310.","journal-title":"Cell Signal"},{"key":"1230_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S0960-9822(03)00049-6","volume":"13","author":"SL Harvey","year":"2003","unstructured":"Harvey SL, Kellogg DR. Conservation of mechanisms controlling entry into mitosis: budding yeast WEE1 delays entry into mitosis and is required for cell size control. Curr Biol. 2003;13:264\u201375.","journal-title":"Curr Biol"},{"key":"1230_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2020.111694","volume":"819\u2013820","author":"CR Elb\u00e6k","year":"2020","unstructured":"Elb\u00e6k CR, Petrosius V, S\u00f8rensen CS. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry. Mutat Res. 2020;819\u2013820:111694.","journal-title":"Mutat Res"},{"key":"1230_CR22","doi-asserted-by":"publisher","first-page":"15160","DOI":"10.1073\/pnas.1505283112","volume":"112","author":"AM Heijink","year":"2015","unstructured":"Heijink AM, Blomen VA, Bisteau X, Degener F, Matsushita FY, Kaldis P, et al. A haploid genetic screen identifies the G1\/S regulatory machinery as a determinant of WEE1 inhibitor sensitivity. Proc Natl Acad Sci USA. 2015;112:15160\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1230_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0320","volume":"2","author":"M Aarts","year":"2012","unstructured":"Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2012;2:524\u201339.","journal-title":"Cancer Discov"},{"key":"1230_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005120","volume":"4","author":"E Iorns","year":"2009","unstructured":"Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, Mackay A, et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS ONE. 2009;4:e5120.","journal-title":"PLoS ONE"},{"key":"1230_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ygyno.2014.07.102","volume":"135","author":"A Slipicevic","year":"2014","unstructured":"Slipicevic A, Holth A, Hellesylt E, Trop\u00e9 CG, Davidson B, Fl\u00f8renes VA. WEE1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. Gynecol Oncol. 2014;135:118\u201324.","journal-title":"Gynecol Oncol"},{"key":"1230_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038254","volume":"7","author":"GI Magnussen","year":"2012","unstructured":"Magnussen GI, Holm R, Emilsen E, Rosnes AKR, Slipicevic A, Fl\u00f8renes VA. High expression of WEE1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS ONE. 2012;7:e38254.","journal-title":"PLoS ONE"},{"key":"1230_CR27","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.4161\/cc.26062","volume":"12","author":"K Do","year":"2013","unstructured":"Do K, Doroshow JH, Kummar S. WEE1 kinase as a target for cancer therapy. Cell Cycle. 2013;12:3159\u201364.","journal-title":"Cell Cycle"},{"key":"1230_CR28","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","volume":"37","author":"CJ Matheson","year":"2016","unstructured":"Matheson CJ, Backos DS, Reigan P. Targeting WEE1 kinase in cancer. Trends Pharmacol Sci. 2016;37:872\u201381.","journal-title":"Trends Pharmacol Sci"},{"key":"1230_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-020-00959-2","volume":"13","author":"A Ghelli Luserna di Ror\u00e0","year":"2020","unstructured":"Ghelli Luserna di Ror\u00e0 A, Cerchione C, Martinelli G, Simonetti G. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. J Hematol Oncol. 2020;13:126.","journal-title":"J Hematol Oncol"},{"key":"1230_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11912-021-01098-8","volume":"23","author":"A Kong","year":"2021","unstructured":"Kong A, Mehanna H. WEE1 inhibitor: clinical development. Curr Oncol Rep. 2021;23:107.","journal-title":"Curr Oncol Rep."},{"key":"1230_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104233","volume":"193","author":"C Zhang","year":"2024","unstructured":"Zhang C, Peng K, Liu Q, Huang Q, Liu T. Adavosertib and beyond: biomarkers, drug combination and toxicity of WEE1 inhibitors. Crit Rev Oncol Hematol. 2024;193:104233.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1230_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057523","volume":"8","author":"JM Kreahling","year":"2013","unstructured":"Kreahling JM, Foroutan P, Reed D, Martinez G, Razabdouski T, Bui MM, et al. WEE1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLoS ONE. 2013;8:e57523.","journal-title":"PLoS ONE"},{"key":"1230_CR33","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10120-021-01176-7","volume":"24","author":"M-H Jin","year":"2021","unstructured":"Jin M-H, Nam A-R, Bang J-H, Oh K-S, Seo H-R, Kim J-M, et al. WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers. Gastric Cancer. 2021;24:1003\u201320.","journal-title":"Gastric Cancer"},{"key":"1230_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2021.103203","volume":"107","author":"S Vakili-Samiani","year":"2021","unstructured":"Vakili-Samiani S, Turki Jalil A, Abdelbasset WK, Yumashev AV, Karpisheh V, Jalali P, et al. Targeting WEE1 kinase as a therapeutic approach in Hematological Malignancies. DNA Repair. 2021;107:103203.","journal-title":"DNA Repair"},{"key":"1230_CR35","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.bbrc.2019.08.163","volume":"519","author":"RSS Barbosa","year":"2019","unstructured":"Barbosa RSS, Dantonio PM, Guimar\u00e3es T, de Oliveira MB, Fook Alves VL, Sandes AF, et al. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines. Biochem Biophys Res Commun. 2019;519:597\u2013604.","journal-title":"Biochem Biophys Res Commun"},{"key":"1230_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.16614","volume":"191","author":"L Liang","year":"2020","unstructured":"Liang L, He Y, Wang H, Zhou H, Xiao L, Ye M, et al. The WEE1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma. Br J Haematol. 2020;191:62\u201376.","journal-title":"Br J Haematol"},{"key":"1230_CR37","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-020-0745-9","volume":"34","author":"L Xing","year":"2020","unstructured":"Xing L, Lin L, Yu T, Li Y, Cho S-F, Liu J, et al. A novel BCMA PBD-ADC with ATM\/ATR\/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020;34:2150\u201362.","journal-title":"Leukemia"},{"key":"1230_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1271847","volume":"13","author":"A Bruyer","year":"2023","unstructured":"Bruyer A, Dutrieux L, de Boussac H, Martin T, Chemlal D, Robert N, et al. Combined inhibition of WEE1 and Chk1 as a therapeutic strategy in multiple myeloma. Front Oncol. 2023;13:1271847.","journal-title":"Front Oncol"},{"key":"1230_CR39","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41375-023-02071-z","volume":"38","author":"C Pfeiffer","year":"2024","unstructured":"Pfeiffer C, Grandits AM, Asnagli H, Schneller A, Huber J, Zojer N, et al. CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1. Leukemia. 2024;38:181\u201392.","journal-title":"Leukemia"},{"key":"1230_CR40","doi-asserted-by":"publisher","unstructured":"Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, et al. Genomic basis of multiple myeloma subtypes from the MMRF CoMMpass Study. bioRxiv. medRxiv; 2021. https:\/\/doi.org\/10.1101\/2021.08.02.21261211.","DOI":"10.1101\/2021.08.02.21261211"},{"key":"1230_CR41","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R. et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024;56:1878\u201389.","journal-title":"Nat Genet"},{"key":"1230_CR42","doi-asserted-by":"publisher","first-page":"D497","DOI":"10.1093\/nar\/gkh070","volume":"32","author":"S Peri","year":"2004","unstructured":"Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath V, Muthusamy B, et al. Human Protein Reference Database as a discovery resource for proteomics. Nucleic Acids Res. 2004;32:D497\u2013501.","journal-title":"Nucleic Acids Res"},{"key":"1230_CR43","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","volume":"107","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, et al. Total Therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006;107:2633\u20138.","journal-title":"Blood"},{"key":"1230_CR44","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1182\/blood-2012-04-421883","volume":"120","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, et al. Second malignancies in total Therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood. 2012;120:1597\u2013600.","journal-title":"Blood"},{"key":"1230_CR45","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/sim.1203","volume":"21","author":"P Royston","year":"2002","unstructured":"Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21:2175\u201397.","journal-title":"Stat Med"},{"key":"1230_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-01938-0","volume":"4","author":"EH Rustad","year":"2021","unstructured":"Rustad EH, Nadeu F, Angelopoulos N, Ziccheddu B, Bolli N, Puente XS, et al. mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies. Commun Biol. 2021;4:424.","journal-title":"Commun Biol"},{"key":"1230_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6:6997.","journal-title":"Nat Commun"},{"key":"1230_CR48","doi-asserted-by":"publisher","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","volume":"45","author":"SA Forbes","year":"2017","unstructured":"Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45:D777\u201383.","journal-title":"Nucleic Acids Res"},{"key":"1230_CR49","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","volume":"1","author":"EH Rustad","year":"2020","unstructured":"Rustad EH, Yellapantula VD, Glodzik D, Maclachlan KH, Diamond B, Boyle EM, et al. Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 2020;1:258\u201373.","journal-title":"Blood Cancer Discov"},{"key":"1230_CR50","doi-asserted-by":"publisher","unstructured":"Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests. Ann Appl Stat. 2008;2. https:\/\/doi.org\/10.1214\/08-aoas169","DOI":"10.1214\/08-aoas169"},{"key":"1230_CR51","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/nar\/gkg034","volume":"31","author":"C von Mering","year":"2003","unstructured":"von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31:258\u201361.","journal-title":"Nucleic Acids Res"},{"key":"1230_CR52","doi-asserted-by":"crossref","unstructured":"Breiman L. Random Forests. Machine Learning. 2001;45:5\u201332.","DOI":"10.1023\/A:1010933404324"},{"key":"1230_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"1230_CR54","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1230_CR55","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267\u201373.","journal-title":"Nat Genet"},{"key":"1230_CR56","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"1230_CR57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00432-023-05527-y","volume":"150","author":"Z Wang","year":"2024","unstructured":"Wang Z, Li W, Li F, Xiao R. An update of predictive biomarkers related to WEE1 inhibition in cancer therapy. J Cancer Res Clin Oncol. 2024;150:13.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01230-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01230-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01230-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:04:44Z","timestamp":1740038684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01230-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1230"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01230-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.20.613788","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SZU: research funding: Amgen, BMS\/Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, Takeda. Consulting\/Advisory Board: AbbVie, Amgen, BMS, Celgene, Genentech, Gilead, GSK, Janssen, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}